Table 1.
| A: Demographic and clinical characteristics of the study groups from PENN cohort | |||
|---|---|---|---|
| Parameter | Psoriasis (N=122) | Control (N=109) | P value |
| Demographic and Clinical Characteristics | |||
| Age, years | 45.2±13.6 | 48.3±8.3 | 0.02 |
| Male Gender, N (%) | 68 (60%) | 60 (55%) | 0.49 |
| Hypertension, N (%) | 39 (34.5%) | 31 (29%) | 0.35 |
| Type 2 DM, N (%) | 10 (8.8%) | 0 (0%) | <0.01 |
| Current Smoker, N (%) | 8 (7%) | 0 (0%) | <0.01 |
| Statin use, N (%) | 33 (27%) | 15 (14%) | 0.12 |
| Clinical and Lab Parameters | |||
| Body Mass Index, kg/m2 | 30.6±8.1 | 27.6±4.6 | <0.0001 |
| Systolic blood pressure, mm Hg | 130.2±17.0 | 127.2±16.2 | 0.26 |
| Diastolic blood pressure, mm Hg | 78.9±10.7 | 78.4±10.1 | 0.38 |
| Total Cholesterol, mg/dL | 191.1±34.4 | 211.6±38.0 | <0.0001 |
| Low-Density Lipoprotein cholesterol, mg/dL |
111.8±28.8 | 134.9±35.3 | <0.0001 |
| High-Density Lipoprotein cholesterol, mg/dL |
48.2 ±15.7 | 51.5±14.2 | 0.05 |
| Triglycerides, mg/dL [Median (IQR)] | 127 (78–190) | 122 (88–156) | 0.34 |
| Glucose, mg/dL | 92.5±37.1 | 92.3±11.7 | 0.47 |
| Framingham Risk Score [Median (IQR)] | 5 (3–9) | 5 (3–8) | 0.05 |
| Insulin, µU/mL [Median (IQR)] | 17.7 (11.6–29.7) | 6.7 (4.4–9.8) | <0.0001 |
| HOMA-IR [Median (IQR)] | 3.3 (1.3–6.4) | 1.5 (0.9–2.2) | <0.0001 |
| Hs-CRP, mg/L [Median (IQR)] | 3.3 (0.84–9.85) | 1.1 (0.5–2.3) | 0.02 |
| GlycA, µmol/L | 408.8±75.4 | 289.4±60.2 | <0.0001 |
| Psoriasis Characteristics | |||
| Body Surface Area affected [Median (IQR)] | 3 (1–7) | - | - |
| Systemic or Biologic Treatment, N (%) | 13 (12%) | - | - |
| B: Demographic and clinical characteristics of the study groups from NIH cohort. | |||
|---|---|---|---|
| Parameter | Psoriasis (N=151) | Control (N=30) | P value |
| Demographic and Clinical Characteristics | |||
| Age, years | 50.2±12.9 | 46.8±8.9 | 0.15 |
| Male Gender, N (%) | 85 (56%) | 20 (67%) | 0.73 |
| Hypertension, N (%) | 40 (27%) | 7 (23%) | 0.72 |
| Type 2 DM, N (%) | 14 (9%) | 3 (10%) | 0.9 |
| Hyperlipidemia, N (%) | 71 (47%) | 14 (47%) | 0.98 |
| Metabolic Syndrome, N (%) | 35 (23%) | 5 (17%) | 0.5 |
| Current Smokers, N (%) | 13 (9%) | 1 (3%) | 0.32 |
| Statin Use, N (%) | 48 (32%) | 9 (30%) | 0.9 |
| Clinical and Laboratory Values | |||
| BMI, kg/m2 | 29.1±6.0 | 28.2±5.2 | 0.21 |
| SBP, mm Hg | 123.7±14.5 | 112.4±11.8 | <0.001 |
| DBP, mm Hg | 72.9±10 | 70.3±8.2 | 0.1 |
| Total Cholesterol, mg/dL | 182.4±36.5 | 188.3±38.7 | 0.21 |
| Low-Density Lipoprotein cholesterol, mg/dL | 101.7±29.8 | 105.3±33.3 | 0.29 |
| High-Density Lipoprotein cholesterol, mg/dL | 56.5±18.3 | 53.2±18.2 | 0.18 |
| Triglycerides, mg/dL | 100.5 (76–138) | 108.5 (83–173) | 0.17 |
| Apolipoprotein A1, mg/dL | 158±30.7 | 150±29.1 | 0.1 |
| Apolipoprotein B, mg/dL | 90±19.6 | 87.6±22 | 0.33 |
| Framingham Risk Score, Median (IQR) | 3 (1–6) | 3 (1–5) | 0.87 |
| Glucose, mg/dL | 100.2±16.6 | 97.2±13.4 | 0.17 |
| Insulin, µU/mL [Median (IQR)] | 11.1 (7.2–19.3) | 9.9 (8.2–15.9) | 0.72 |
| HOMA-IR, Median (IQR) | 2.77 (1.58–4.88) | 2.38 (1.74–5.14) | 0.67 |
| Hs-CRP, mg/L [Median (IQR)] | 1.80 (0.71–4.22) | 1.35 (0.79–2.40) | 0.24 |
| GlycA, µmol/L | 415.8±63.2 | 346.2±46 | <0.0001 |
| Psoriasis Characteristics | |||
| Disease duration, years [Median (IQR)] | 20 (8–30) | N/A | |
| Body Surface Area affected, Median (IQR) | 4.1 (2.1–13.5) | N/A | |
| PASI score, Median (IQR) | 5.8 (3–10.1) | N/A | |
| Systemic or Biologic Treatment, N (%) | 55 (37%) | N/A | |
| Vascular Inflammation by FDG PET/CT | |||
| Aortic Vascular Inflammation | 1.70±0.26 | 1.59±0.13 | 0.01 |
| Coronary Artery Disease by CCTA | |||
| Total Burden of Coronary Artery Disease | 1.12±0.46 | 0.99±0.25 | 0.01 |
Continuous variables are expressed as Mean ±S.D unless specified otherwise and categorical variables as %. P values were calculated by Student’s t-test for continuous variable and Pearson’s chi-square test for categorical variables.
DM: Diabetes Mellitus, HOMA-IR: Homeostasis Model Assessment of Insulin Resistance, Hs-CRP: High-sensitivity C-reactive protein, PASI: Psoriasis area and severity index